0000000000054430

AUTHOR

Michael Heike

showing 26 related works from this author

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with…

2002

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens. Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, g…

Malemedicine.medical_specialtyAntimetabolites AntineoplasticPalliative careTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSalvage therapyAntineoplastic AgentsIrinotecanGastroenterologyFolinic acidInternal medicineMucositisMedicineHumansNeoplasm MetastasisInfusions IntravenousAgedRetrospective StudiesSalvage TherapyChemotherapybusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicOxaliplatinSurgeryIrinotecanOxaliplatinFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells

1994

A limiting-dilution assay was developed and used to determine the frequency of autologous tumor-reactive cytotoxic T lymphocytes (CTL) in peripheral blood of a melanoma patient MZ2, who has been free of detectable disease since several years. In this patient, the frequencies of tumor-reactive CTL spontaneously varied only by a factor of 1.5. After vaccinations with autologous mutagenized and lethally irradiated tumor cells a two- to tenfold increase in frequencies of tumor-reactive CTL was found within the first 2 weeks. Thereafter, CTL frequencies returned to values measured prior to vaccinations. We conclude, that the limiting-dilution assay applied in this study can detect changes in the…

Cytotoxicity ImmunologicCancer ResearchCellular immunitymedicine.medical_treatmentImmunologyActive immunizationLeukocyte CountImmune systemTumor Cells CulturedmedicineHumansImmunology and AllergyCytotoxic T cellAmelanotic melanomaMelanomaCells Culturedbusiness.industryVaccinationReproducibility of ResultsImmunotherapyT lymphocytemedicine.diseaseCTL*OncologyImmunologyImmunotherapyLymphocyte Culture Test MixedbusinessT-Lymphocytes CytotoxicCancer Immunology Immunotherapy
researchProduct

Heat shock protein-peptide complexes for use in vaccines

1996

Abstract The heat shock proteins gp96, HSP70, and HSP90 are complexed to a diverse array of cellular proteins and peptides as a consequence of their chaperone functions. There is good experimental evidence that vaccination with these heat shock protein-peptide complexes elicit immune responses against chaperoned peptide antigens. As shown with gp96, this requires internalization of the heat shock protein-peptide complexes by macrophages and processing of the chaperoned peptides for class I restricted presentation. Via this process, primarily CD8+ antigen-specific T cells are primed by gp96 vaccination. This might represent a general mechanism for priming of MHC-class I restricted T cells by…

VaccinesbiologyAntigen processingImmunologyAntigen presentationCell BiologyMHC restrictionMajor histocompatibility complexMolecular biologyHsp70Cell biologyAntigenAntigens NeoplasmNeoplasmsHeat shock proteinMHC class Ibiology.proteinAnimalsHumansImmunology and AllergyPeptidesHeat-Shock ProteinsMolecular ChaperonesJournal of Leukocyte Biology
researchProduct

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

1995

Interferon alpha-2a (IFN-alpha) and folinic acid (FA) have been shown to modulate the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect of a combination of 5-FU/FA/IFN-alpha in patients with advanced pancreatic cancer. Sixty previously untreated patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m-2 FU via an intravenous bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million units (MU) of IFN-alpha was administered subcutaneously. The treatment was repeated once a week. Of 57 evaluable patients, eight (14%) had a partial response (PR),…

AdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentLeucovorinAlpha interferonAdenocarcinomaInterferon alpha-2GastroenterologyFolinic acidInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInterferon alfaAgedChemotherapybusiness.industryInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryPancreatic NeoplasmsOncologyFluorouracilFemaleFluorouracilbusinessProgressive diseasemedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer

2000

Preparations of stress protein gp96 from tumor cells are active as tumor vaccines by eliciting immune responses against mixtures of individual tumor peptide antigens which are complexed to gp96. Due to the individual antigenicity of tumors, a vaccine consisting of tumor-derived gp96 has to be prepared individually for each patient from autologous tumor tissue. So far, gp96 expression by human tumors has not been analyzed. Here, we report stable and mostly homogenous expression of gp96 by colorectal cancer, which was enhanced compared to surrounding tumor stroma in 70% to 80% of colorectal cancer specimens. Fewer non-metastatic than metastatic primary cancer specimens showed enhanced gp96 ex…

CA15-3Cancer ResearchColorectal cancerbusiness.industryTumor M2-PKMouse model of colorectal and intestinal cancermedicine.diseaseImmunohistochemistryNeoplasm ProteinsImmune systemOncologyAntigenCell cultureImmunologymedicineHumansCA19-9Colorectal NeoplasmsbusinessHT29 CellsHeat-Shock ProteinsInternational Journal of Cancer
researchProduct

Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells.

1997

The cytokine profile of tumour reactive T cells is likely to play a central role in their function. However, little is known about how cytokine patterns of tumour reactive T cells can be regulated. Here, the authors investigated the influence of exogenous regulatory cytokines in addition to interleukin-2 (IL-2) on cytokine patterns and the proliferation of T cells recognizing an autologous sarcoma cell line. In this system, IL-4 and IL-12 showed the most polarizing influences on tumour reactive T cells. Exogenous IL-4 induced a predominant production of IL-4 while decreasing the interferon-gamma (IFN-gamma) and IL-10 production by tumour reactive T cells. It also stimulated the growth of tu…

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT cellReceptors Antigen T-Cell alpha-betaT-LymphocytesImmunologyBiologyLymphocyte ActivationInterleukin 21Interferon-gammaAntigens CDmedicineTumor Cells CulturedCytotoxic T cellHumansIL-2 receptorFluorescent Antibody Technique IndirectCells CulturedTumor Necrosis Factor-alphaZAP70Receptors Antigen T-Cell gamma-deltaSarcomaGeneral MedicineInterleukin-12Cell biologyClone CellsInterleukin-10Interleukin 10Cytokinemedicine.anatomical_structureInterleukin 12Interleukin-4Scandinavian journal of immunology
researchProduct

T cell specificity and cross reactivity towards enterobacteria,Bacteroides,Bifidobacterium, and antigens from resident intestinal flora in humans

1999

BACKGROUNDT cell responses to normal intestinal bacteria or their products may be important in the immunopathogenesis of chronic enterocolitis.AIMSTo investigate the T cell specificity and cross reactivity towards intestinal bacteria.PATIENTS/METHODST cell clones were isolated with phytohaemagglutinin from peripheral blood and biopsy specimens of inflamed and non-inflamed colon from five patients with inflammatory bowel disease (IBD) and two controls. T cell clones were restimulated with anaerobicBacteroides andBifidobacteria species, enterobacteria, and direct isolates of aerobic intestinal flora. T cell phenotype was analysed by single-cell immunocyte assay.RESULTSAnalysis of 96 T cell cl…

biologyT cellGastroenterologybiology.organism_classificationmedicine.disease_causeCross-reactivityMicrobiologymedicine.anatomical_structureImmune systemAntigenImmunologymedicinebiology.proteinAnaerobic bacteriaBacteroidesBifidobacteriumPhytohaemagglutininGut
researchProduct

Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to…

2003

Abstract Immunization with heat shock proteins (hsp) isolated from cancer cells has been shown to induce a protective antitumor response. The mechanism of hsp-dependent cellular immunity has been attributed to a variety of immunological activities mediated by hsp. Hsp have been shown to bind antigenic peptides, trim the bound peptides by intrinsic enzymatic activity, improve endocytosis of the chaperoned peptides by APCs, and enhance the ability of APCs to stimulate peptide-specific T cells. We have investigated the potential capacity of hsp70 and gp96 to function as a mediator for Ag-specific CTL stimulation in an in vitro model for human melanoma. Repetitive stimulation of PBLs by autolog…

Cellular immunityT cellImmunologyAntigen-Presenting CellsEpitopes T-LymphocyteBiologyLymphocyte ActivationEpitopeInterferon-gammaMART-1 AntigenAntigenAntigens NeoplasmCell Line TumorHLA-A2 AntigenmedicineHumansImmunology and AllergyCytotoxic T cellHSP70 Heat-Shock ProteinsLymphocyte CountAntigen-presenting cellMelanomaHeat-Shock ProteinsCell Line TransformedAntigen PresentationMonophenol MonooxygenaseDendritic CellsMolecular biologyCoculture TechniquesClone CellsNeoplasm ProteinsUp-RegulationCTL*medicine.anatomical_structureCancer cellK562 CellsPeptidesT-Lymphocytes CytotoxicThe Journal of Immunology
researchProduct

Adjuvante und palliative Therapie kolorektaler Karzinome

2008

business.industryMedicineGeneral MedicinebusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.

2003

Although 5-fluorouracil remains the mainstay of treatment for advanced gastric cancer (AGC), no standard chemotherapy regimen exists. Combinations of irinotecan with folinic acid and infusional 5-fluorouracil (5-FU) (ILF) have shown good efficacy with acceptable toxicity in patients with metastatic colorectal cancer. At present, only sparse data on ILF are available for AGC. Therefore we conducted a prospective study of this combination in 25 consecutive patients with metastatic gastric cancer. Median age was 63 years, 10 had received prior chemotherapy and 13 presented initially with peritoneal carcinosis. Treatment consisted of irinotecan 80 mg/m2, folinic acid 500 mg/m2 and infusional 5-…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLeucovorinPilot ProjectsIrinotecanFolinic acidStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)In patientProspective StudiesAgedPharmacologybusiness.industryAdvanced gastric cancerMiddle AgedChemotherapy regimendigestive system diseasesIrinotecanstomatognathic diseasesOncologyFluorouracilToxicityCamptothecinFemaleFluorouracilbusinessmedicine.drugAnti-cancer drugs
researchProduct

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma…

1997

Tumor-reactive CD4+ T cells have been isolated from tumor patients, and their specifity but not T-cell receptor (TCR) repertoire has been analyzed. Since we have described CD4+ sarcoma-reactive T-cell clones, we now sought to determine whether the TCR repertoire of these clones provides information on the spectrum of recognized sarcoma antigens. We analyzed the TCR beta (TCRB) chain repertoire of 19 CD4+ HLA-DR-restricted T-cell clones reactive with the autologous sarcoma cell line MZ-MES-1, with HLA-DR-matched tumor cell lines of different tissue origins and B-cell blasts. We identified 7 different clonotypes, which used a limited set of TCRBV and TCRBJ segments. Although the CDR3 of the d…

CD4-Positive T-LymphocytesCancer ResearchReceptors Antigen T-Cell alpha-betaLymphocyteBiologyPolymerase Chain ReactionInterferon-gammaImmune systemAntigenAntigens NeoplasmStomach NeoplasmsTumor Cells CulturedHLA-DRmedicineHumansMelanomaPan-T antigensT-cell receptorSarcomaHLA-DR AntigensT lymphocyteFetal BloodJunctional diversityClone Cellsmedicine.anatomical_structureOncologyImmunologyInternational Journal of Cancer
researchProduct

Heat Shock Protein Vaccines Against Cancer

1993

Vaccination of mice with heat shock proteins (HSPs) derived from a tumor makes the mice resistant to the tumor from which the HSP was obtained. This phenomenon has been demonstrated with three HSPs--gp96, hsp90, and hsp70. Vaccination with HSPs also elicits antigen-specific cytotoxic T lymphocytes (CTLs). The specific immunogenicity of HSPs derives apparently, not from the HSPs per se, but from the peptides bound to them. These observations provide the basis for a new generation of vaccines against cancer. The HSP-based cancer vaccines circumvent two of the most intractable hurdles to cancer immunotherapy. One of them is the possibility that human cancers, like cancers of experimental anima…

Cancer Researchmedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaBiologyInfectionsEpitopeMiceImmune systemAntigenCancer immunotherapyHeat shock proteinmedicineAnimalsImmunology and AllergyCytotoxic T cellHeat-Shock ProteinsPharmacologyMice Inbred BALB CMice Inbred C3HHistocompatibility Antigens Class IVaccinationCancerhemic and immune systemsImmunotherapymedicine.diseaseImmunologySarcoma ExperimentalT-Lymphocytes CytotoxicJournal of Immunotherapy
researchProduct

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in…

2005

An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m(-2), LV 500 mg m(-2), 24-h 5-FU 2000 mg m(-2), and ELF comprised three once-daily doses of etoposide 120 mg m(-2), LV 300 mg m(-2), 5-FU 500 mg m(-2). In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classLeucovorinPhases of clinical researchNeutropeniaAdenocarcinomaIrinotecanAntimetaboliteGastroenterologygastricStomach NeoplasmsInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans5-fluorouracilStomach cancerEtoposidePeritoneal NeoplasmsAgedEtoposideNeoplasm StagingLevoleucovorinbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgerymetastaticIrinotecanELFTreatment OutcomeOncologyTolerabilityFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilbusinessILFmedicine.drugBritish Journal of Cancer
researchProduct

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and…

2014

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drugJournal of Clinical Oncology
researchProduct

New cell lines of gastric and pancreatic cancer: distinct morphology, growth characteristics, expression of epithelial and immunoregulatory antigens.

1995

Two new cell lines from stomach cancers and one from a pancreatic carcinoma are presented. MZ-GC-1 was established from a hepatic metastasis of a well differentiated gastric adenocarcinoma. MZ-GC-2 was derived from ascites induced by a poorly differentiated gastric adenocarcinoma. MZ-PC-1 originated from the pleural effusion of a moderately well differentiated pancreatic ductal adenocarcinoma. MZ-GC-1 cells were adherent and partially polarized, connected tightly via desmosomes. In contrast MZ-GC-2 cells consisted of slightly adherent or floating subpopulations and displayed no desmosomes. MZ-PC-1 cells were adherent and showed polarized growth, connected by apical junctional complexes. Cel…

Pathologymedicine.medical_specialtyCell divisionCellular differentiationCellBiologyAdenocarcinomaEpitheliumPathology and Forensic MedicineCytokeratinNude mouseStomach NeoplasmsPancreatic cancermedicineBiomarkers TumorHumansNeoplasm MetastasisMolecular BiologyCell Line TransformedLiver NeoplasmsCell DifferentiationCell BiologyGeneral Medicinebiology.organism_classificationmedicine.diseasePancreatic NeoplasmsMicroscopy Electronmedicine.anatomical_structureCell cultureAntigens SurfaceCancer researchMicroscopy Electron ScanningPancreasCell DivisionVirchows Archiv : an international journal of pathology
researchProduct

Immune Response to Tumor Stress Proteins—Implications for Vaccine Development Against Cancer

2000

Publisher Summary Stress proteins or heat shock proteins (HSP) belong to the most conserved proteins. The conservation of stress proteins stems from their basic and vital role in cells: Prevention of protein aggregation under stress and physiological conditions. Stress proteins are important target antigens in autoimmune diseases and during certain bacterial infections. This chapter reviews the immunogenicity of stress proteins of tumor cells, stimulation of T cell response by tumor stress proteins and implications this Tcell response have for immunity against the tumor or autoimmunity. The expression of stress proteins in cancer is altered. An overexpression of constitutively expressed or …

Immune systemAntigenHeat shock proteinImmunogenicityEndoplasmic reticulumMHC class Ibiology.proteinCytotoxic T cellBiologyProtein aggregationCell biology
researchProduct

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with c…

2013

TPS3124^ Background: 15-20% of all patients (pts) diagnosed with colorectal cancer (crc) develop metastases (mets) surgical resection remains the only potentially curative treatment available. Current 5-year survival rate following R0 resection of liver mets lies between 28-39%, recurrence occurs in up to 70% of pts. To date, adjuvant chemotherapy has not significantly improved clinical outcomes. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active MUC1-specific cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in crc pts following R0/R1 resection of liver mets known to highly express MUC1 gly…

Cancer Researchmedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentImmunotherapymedicine.diseasePlaceboGastroenterologySurgeryDouble blindOncologyCurative treatmentInternal medicineMedicineTecemotideIn patientMetastasectomybusinessJournal of Clinical Oncology
researchProduct

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following…

2012

TPS3641^ Background: Approximately 15-20% of patients diagnosed with colorectal cancer (crc) develop metastatic disease. Surgical resection remains the only potentially curative treatment. 5-year survival following R0-resection of liver metastases lies ~28 -39%. Recurrence occurs in ~70% of pts. Adjuvant chemotherapy has not significantly improved clinical outcomes. The primary objective of the LICC trial (L-BLP25 in Colorectal Cancer) is to analyze whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer pts following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in …

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerbusiness.industrymedicine.medical_treatmentDiseasemedicine.diseasePlaceboDouble blindOncologyCancer immunotherapyTolerabilityInternal medicinemedicineIn patientMetastasectomybusinessJournal of Clinical Oncology
researchProduct

Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and Dendritic Cells: Superiority of HSP60

2002

Abstract One essential immunoregulatory function of heat shock protein (HSP) is activation of the innate immune system. We investigated the activation of human monocytes and monocyte-derived dendritic cells (DC) by recombinant human HSP60, human inducible HSP72, and preparations of human gp96 and HSP70 under stringent conditions, in the absence of serum and with highly purified monocytes. HSP60 induced human DC maturation and activated human DC to secrete proinflammatory cytokines. HSP72 induced DC maturation to a lesser extent, but activated human monocytes and immature DC as efficiently as HSP60 to release proinflammatory cytokines. The independence of the effects of HSP60 and HSP72 from …

T-Lymphocytesmedicine.medical_treatmentImmunologyHSP72 Heat-Shock ProteinsPeptide bindingBiologyLymphocyte ActivationMonocytesProinflammatory cytokineAntigens NeoplasmHeat shock proteinmedicineHumansImmunology and AllergyHSP70 Heat-Shock ProteinsSecretionHeat-Shock ProteinsInnate immune systemCell DifferentiationChaperonin 60Dendritic CellsMolecular biologyCoculture TechniquesRecombinant ProteinsHsp70CytokineCytokinesHSP60Inflammation MediatorsSignal TransductionThe Journal of Immunology
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-class-II-restricted autologous T cells

1996

Defects in the generation and transport of antigenic peptides within tumor cells will lead to the expression of unstable HLA-class-I molecules on the cell surface. These defects will allow tumor cells to escape an MHC-class-I-restricted T-cell response. Recently, we described an exclusively HLA-class-II-restricted autologous T-cell response against a human sarcoma cell line MZ-MES-1 in vitro. Here, we show that surface HLA-class-I molecules of MZ-MES-1 cells are unstable at physiological temperature. HLA-class-I surface expression of MZ-MES-1 cells could be strongly enhanced by culture at low temperature in contrast to various other cell lines analyzed in parallel. Furthermore, culture at l…

Cancer ResearchCellular immunityanimal structuresAntigen presentationCellHuman leukocyte antigenBiologyIn vitroCell biologyImmune systemmedicine.anatomical_structureOncologyCell cultureImmunologymedicineInterferon gammamedicine.drugInternational Journal of Cancer
researchProduct

Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells.

2003

Certain autonomous parvoviruses preferentially replicate in and kill in vitro-transformed cells and may reduce the incidence of spontaneous and implanted tumors in animals. Hence, these viruses and their derivatives are currently under evaluation as antitumor vectors. However, the mechanisms underlying their tumor-suppressing properties are not yet understood. We asked whether the lytic parvovirus H1 may enhance the immunogenicity of infected tumor cells. Out of human melanoma and gastrointestinal tumor cells, we selected the cell line SK29-Mel-1 being very susceptible to H1-induced apoptotic killing. Here, no upregulation of HLA class I and costimulatory molecules could be observed followi…

Cancer ResearchTime FactorsCell SurvivalGenetic VectorsApoptosisHSP72 Heat-Shock ProteinsVirusParvovirusImmune systemCell Line TumorHumansHSP70 Heat-Shock ProteinsTransgenesMolecular BiologyMelanomaCells CulturedHeat-Shock ProteinsbiologyParvovirusImmunogenicityHSC70 Heat-Shock Proteinsbiology.organism_classificationVirologyOncolytic virusUp-RegulationCell killingViral replicationCell cultureCancer researchMolecular MedicineCarrier ProteinsCancer gene therapy
researchProduct

Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines.

1999

Vaccination of inbred mice with tumor-derived stress proteins hsp70, hsp90, and gp96/grp94 elicits a protective immunity to the tumor from which the vaccine was purified. There is now comprehensive experimental evidence that the antigenicity of tumor-derived hsp70, hsp90, and gp96 preparations results from diverse arrays of endogenous peptide antigens complexed with these stress proteins. Vaccination with tumor-derived stress protein/peptide complexes leads to their uptake and processing by professional antigen-presenting cells and to presentation of associated tumor peptide antigens to cytotoxic T cells. This induces a tumor-specific cytotoxic T cell response. The attractiveness of the con…

AntigenicityPeptideMice Inbred StrainsBiologyBiochemistryCancer VaccinesMiceImmune systemAntigenAntigens NeoplasmHeat shock proteinHistocompatibility AntigensNeoplasmsCytotoxic T cellAnimalsHumansHeat-Shock ProteinsPharmacologychemistry.chemical_classificationHsp90Hsp70chemistryImmunologyCancer researchbiology.proteinMolecular ChaperonesT-Lymphocytes CytotoxicBiochemical pharmacology
researchProduct

Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal c…

2003

The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials. Therefore, we carefully evaluated the safety and efficacy of this regimen, with high value placed on the management of delayed diarrhea. Forty-six patients with metastatic colorectal cancer received this first-line treatment in nine German outpatient clinics. Dose reductions were mandatory from the first cycle in case of toxicity grade2. Chemotherapy was administered only to diarrhea-free p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLeucovorinEarly deathIrinotecanFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsAmbulatory CaremedicineHumansPharmacology (medical)Prospective StudiesAgedPharmacologyChemotherapybusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateIrinotecanOncologyFluorouracilCamptothecinFemaleFluorouracilFirst line chemotherapyColorectal Neoplasmsbusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epiru…

2019

Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours. Methods In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and t…

medicine.medical_specialtyeducation.field_of_studyChemotherapybusiness.industrymedicine.medical_treatmentPopulationMedizinGeneral MedicinePerioperative030204 cardiovascular system & hematologyGastroenterologyOxaliplatinCapecitabine03 medical and health sciences0302 clinical medicineDocetaxelFluorouracilInternal medicineMedicine030212 general & internal medicinebusinesseducationmedicine.drugEpirubicinThe Lancet
researchProduct

Parvovirus H-1-Induced Tumor Cell Death Enhances Human Immune Response In Vitro via Increased Phagocytosis, Maturation, and Cross-Presentation by Den…

2005

Oncotropic and oncolytic viruses have attracted high attention as antitumor agents because they preferentially kill cancer cells in vitro and reduce the incidence of spontaneous, induced, or implanted animal tumors. Some autonomous parvoviruses (H-1, minute virus of mice) and derived recombinant vectors are currently under preclinical evaluation. Still not fully understood, their antitumor properties involve more than just tumor cell killing. Because wild-type parvovirus-mediated tumor cell lysates (TCLs) may trigger antigen-presenting cells (APCs) to augment the host immune repertoire, we analyzed phagocytosis, maturation, and crosspresentation of H-1-induced TCLs by human dendritic cells …

Skin NeoplasmsParvovirus H-1ApoptosisBiologyParvovirusMiceImmune systemCross-PrimingAntigenPhagocytosisAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedGeneticsCytotoxic T cellAnimalsHumansMelanomaMolecular BiologyCryopreservationCross-presentationCell DifferentiationDendritic cellDendritic CellsOncolytic virusCancer cellImmunologyCancer researchMolecular MedicineT-Lymphocytes CytotoxicHuman Gene Therapy
researchProduct